63rd ASH Annual Meeting and Exposition: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Reoptimizing Standards and Redefining Approaches

Oral and Poster Abstracts
Oral

Epidemiology, Clinical Research, Plasma Cell Disorders, Diseases, Real World Evidence, Lymphoid Malignancies

Hall A1 (Georgia World Congress Center)

Moderators:

Juan Du, MD, PhD, Shanghai Changzheng hospital, Naval Medical University and Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami

Disclosures:

Landgren: Amgen: Honoraria, Research Funding; Janssen: Honoraria, Other, Research Funding; Celgene: Research Funding; BMS: Research Funding; Adaptive Biotech: Honoraria; Theradex: Other: IDMC.

The current state of the definitions for multiple myeloma and related precursor conditions include a range of unresolved clinical and scientific questions. Many of these questions can be studied in larger retrospective databases, clinical epidemiology cohort studies, or smaller molecular studies with clinically well-annotated samples. Dr. Burgos will present results from over 5000 cases with monoclonal gammopathies investigated by flowcytometry. Their study shows how an algorithm which can be installed in clinical flow cytometry software can be used to generate automated classifications across the spectrum of monoclonal gammopathies. Dr. Long will discuss how current reference intervals for serum free light-chain (FLC) and FLC-ratio are inaccurate for patients with decreased kidney function. Based on the large prospective iStopMM study, new reference intervals will be proposed for serum FLC and FLC-ratio, for use in patients with chronic kidney disease which also seem to be accurate in patients on dialysis. Dr. Visram will address that current smoldering multiple myeloma (SMM) prognostication models - routinely used in clinical practice - indeed were developed for use at diagnosis. This talk will focus on how one dynamically can risk stratify patients post-diagnosis, and how to better identify patients with evolving disease. Dr. Puig will discuss comparisons of blood based immunofixation electrophoresis (IFE), quantitative immunoprecipitation mass spectrometry, liquid chromatography mass spectrometry (LC-MS), and bone marrow-based MRD assays. Focus of the investigations include capacity to identify the presence of disease and ability to determine prognosis. Dr. Samur will present results from their studies designed to distinguish genomic hallmarks of low-risk (vs high-risk) smoldering multiple myeloma. Using transcriptome, epigenome and whole genome profiling they have interrogated samples from patients with clinical follow-up data. Dr. Jelinek will discuss findings from their study investigating circulating plasma cells (sPCs) measured by 8 color flow cytometry in 402 multiple myeloma patients. Scope of these investigations is to evaluate the prognostic significance of cPCs, and also to define cut-offs for risk stratification.

4:30 PM

541

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Leire Burgos¹^*, Luis Esteban Tamariz-Amador, MD²^*, Noemí Puig, MD, PhD³^*, María Teresa Cedena, MD, PhD⁴^*, Tomas Jelinek, MD, PhD⁵, Sarah K Johnson, PhD⁶, Paolo Milani, MD, PhD⁷, Lourdes Cordon⁸^*, José J Pérez³^*, Marta Lasa¹^*, Rosalinda Termini⁹^*, Albert Oriol, MD¹⁰^*, Miguel-Teodoro Hernández, MD, PhD¹¹^*, Luis Palomera, MD, PhD¹²^*, Rafael Martinez Martinez¹³^*, Javier de la Rubia, MD, PhD¹⁴^*, Felipe De Arriba, PhD¹⁵^*, Rafael Rios, MD, PhD¹⁶^*, Maria Esther González¹⁷^*, Mercedes Gironella, MD¹⁸^*, Valentin Cabañas, MD¹⁹^*, Maria Casanova, MD²⁰^*, Isabel Krsnik²¹^*, Albert Pérez, MD²²^*, Veronica Gonzalez De La Calle, MD, PhD²³^*, Paula Rodríguez-Otero, MD, PhD²⁴^*, Vladimir Maisnar, MD²⁵^*, Roman Hajek, MD, PhD²⁶, Frits van Rhee, MD PhD²⁷, Victor H Jimenez-Zepeda, MD²⁸, Giovanni Palladini²⁹, Paolo Milani³⁰^*, Alberto Orfao, MD, PhD³, Laura Rosinol³¹^*, Joan Bladé Creixenti³², Joaquín Martínez-López³³^*, Juan-José Lahuerta, MD, PhD³⁴^*, Maria-Victoria Mateos³⁵, Jesús F. San-Miguel¹ and Bruno Paiva, PhD¹^*

¹Centro de Investigación Médica Aplicada, University of Navarra, IDISNA, CIBERONC, Clínica Universidad de Navarra, Pamplona, Spain
²Centro de Investigación Médica Aplicada, University of Navarra, IDISNA, CIBERONC, Clínica Universidad de Navarra, Pamplona, Navarra, Spain
³Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
⁴Hematology Department, Hospital Universitario 12 de Octubre, CIBERONC, Instituto de Investigación IMAS12, Madrid, Spain
⁵Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic
⁶Myeloma Center/Division of Hematology Oncology/Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR
⁷Amyloidosis Research and Treatment Center, Department of Molecular Medicine, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
⁸Hospital Universitario La Fe, Valencia, Spain
⁹Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona, Spain
¹⁰Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
¹¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
¹²Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
¹³Hospital Clínico San Carlos, Madrid, Spain
¹⁴Hematology Department, University Hospital La Fe, Valencia, Spain
¹⁵Hospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
¹⁶Hospital Universitario Virgen de las Nieves de Granada, Instituto de Investigación Biosanitaria IBS GRANADA, Granada, Spain
¹⁷Hospital de Cabueñes, Gijón, Spain
¹⁸Department of Hematology, University Hospital Vall d’Hebron, Barcelona, Spain
¹⁹Hospital Clínico Universitario Virgen de la Arrixaca. IMIB-Arrixaca. University of Murcia, Murcia, Spain
²⁰Hematology Department, Hospital Costa del Sol Marbella, Marbella, Spain
²¹Hospital Universitario Puerta de Hierro, Hospital, Madrid, Spain
²²Hospital Universitario Son Espases, Palma, Spain
²³Departamento de Hematología, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
²⁴Clinica Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Navarra, Spain
²⁵4th Department of Medicine - Haematology, Charles University Hospital, Hradec Králové, Czech Republic
²⁶Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
²⁷Myeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR
²⁸Tom Baker Cancer Center, Department of Hematology, University of Calgary, Calgary, AB, Canada
²⁹Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, PV, Italy
³⁰Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matt, Pavia, ITA
³¹Amyloidosis and Myeloma Unit. Department of Hematology. Hospital Clínic de Barcelona. IDIBAPS., Barcelona, Spain
³²Amyloidosis and Multiple Myeloma Unit, Department of Hematology, IDIBAPS, Hospital Clínic, Barcelona, Spain, Barcelona, Spain
³³Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, CNIO, CIBERONC, Madrid, Spain
³⁴Hospital 12 de Octubre, CIBERONC, Madrid, Spain
³⁵Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain

4:45 PM

542

Defining New Reference Intervals for Serum Free Light Chains in Individuals with Reduced Kidney Function: Results of the Population- Based on Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM) Study

Thorir Einarsson Long, MD, PhD^1,2^*, Olafur Skuli Indridason, MD, MHS³^*, Runolfur Palsson, MD^4,5^*, Sæmundur Rögnvaldsson, MD⁵^*, Thorvardur Jon Love, MD, PhD⁶^*, Sigrun Thorsteinsdottir, MD, PhD^6,7, Ingigerdur Solveig Sverrisdottir, MD, BSc⁵^*, Brynjar Vidarsson, MD⁴, Pall Torfi Onundarson, MD⁴, Bjarni Agnar Agnarsson, MD⁴^*, Margret Sigurdardottir, MD⁴^*, Ingunn Thorsteinsdottir, MD, PhD⁴^*, Isleifur Olafsson, MD, PhD⁴^*, Asdis Rosa Thordardottir⁶^*, Elias Eythorsson, MD, PhD⁴^*, Asbjorn Jonsson, MD⁴^*, Gauti Gislason⁸^*, Andri Olafsson⁶^*, Hlif Steingrimsdottir, MD⁹^*, Petros Kampanis, PhD¹⁰^*, Malin Hultcrantz, MD PhD¹¹, Brian G.M. Durie, MD¹², Stephen Harding, PhD¹³, Ola Landgren, MD¹⁴ and Sigurdur Yngvi Kristinsson, MD, PhD^4,6

¹University of Iceland, Reykjavik, AL, Iceland
²Skånes University Hospital, Lund, Sweden
³Landspitali–The National University Hospital of Iceland, Reykjavik, Iceland
⁴Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland
⁵Faculty of Medicine, University of Iceland, Reykjavík, Iceland
⁶Faculty of Medicine, University of Iceland, Reykjavik, Iceland
⁷Department of Hematology, Rigshospitalet, Copenhagen, Denmark
⁸University of Iceland, Reykjavik, ISL
⁹Landspitali - National University Hospital of Iceland, Reykjavík, Iceland
¹⁰Binding Site Group Ltd., Birmingham, ENG, United Kingdom
¹¹Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹²Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA
¹³The Binding Site Inc., Birmingham, United Kingdom
¹⁴Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami

5:00 PM

543

Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis

Alissa Visram, alisvisram@toh.ca¹^*, S. Vincent Rajkumar, MD²^*, Prashant Kapoor, MD², Angela Dispenzieri, MD², Martha Q. Lacy, MD³, Morie A. Gertz, M.D.², Francis K. Buadi, MB, CHB⁴^*, Suzanne R. Hayman, M.D.², David Dingli, M.D., Ph.D.², Taxiarchis Kourelis, M.D.², Wilson I Gonsalves, MD², Rahma M Warsame, MD², Eli Muchtar, MD², Nelson Leung, MD³, Linda B Baughn, PhD⁵, Robert A. Kyle, MD² and Shaji K Kumar, MD⁶

¹Division of Hematology, Mayo Clinic, Rochester
²Division of Hematology, Mayo Clinic, Rochester, MN
³Division of Hematology, Mayo Clinic Rochester, Rochester, MN
⁴Mayo Clinic Rochester, Division of Hematology, Rochester, MN
⁵Division of Laboratory Genetics, Mayo Clinic, Rochester, MN
⁶Mayo Clinic, Rochester, MN

5:15 PM

544

Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial

Noemi Puig, MD, PhD^1,2, Teresa Contreras Sanfeliciano³^*, Bruno Paiva, PhD⁴^*, María Teresa Cedena, MD, PhD⁵^*, Laura Rosinol⁶^*, Ramón Garcia-Sanz, MD, PhD², Joaquín Martínez-López^7,8,9,10^*, Albert Oriol¹¹^*, María Jesús Blanchard, MD¹²^*, Rafael Rios, MD, PhD¹³^*, Jesus Martin, MD¹⁴^*, Anna Sureda¹⁵, Miguel Hernández¹⁶^*, Javier De La Rubia, MD¹⁷^*, Isabel Krsnik, MD, PhD¹⁸^*, Jose Maria Moraleda, MD, PhD¹⁹^*, Belén Iñigo, MD²⁰^*, Luis Palomera, MD, PhD²¹^*, Cristina Agulló¹^*, Joan Bargay²²^*, Joan Bladé Creixenti^23,24, Jesús San-Miguel, MD, PhD^4,25, Juan-José Lahuerta, MD, PhD²⁶^* and Maria-Victoria Mateos^27,28,29

¹University Hospital of Salamanca, Salamanca, Spain
²Departamento de Hematología, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
³Servicio Análisis Clínicos y Bioquímica Clínica del Complejo Asistencial Salamanca, Complejo Asistencial Salamanca, Salamanca, Spain
⁴Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain
⁵Hematology Department, Hospital Universitario 12 de Octubre, CIBERONC, Instituto de Investigación IMAS12, Madrid, Spain
⁶Hematology, Hematology Department, Hospital Clinic i Provincial, IDIBAPS, Barcelona, Spain
⁷Hospital 12 De Octubre, Madrid, Spain
⁸H12O-CNIO Clinical research unit, CIBERONC, Complutense University, Madrid, Spain
⁹Department of Hematology, Hospital Universitario 12 de Octubre; H12O-CNIO Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain
¹⁰Hematology Department, Hospital Universitario 12 de Octubre, CNIO, Complutense University, Madrid, Spain
¹¹Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
¹²Hematology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain
¹³Hospital Universitario Virgen de las Nieves de Granada, Instituto de Investigación Biosanitaria IBS GRANADA, Granada, Spain
¹⁴Hospital Universitario V. Rocio, Sevilla, ESP
¹⁵Clinical Hematology Department, Institut Català d'Oncologia, Hospital Duran i Reynals, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
¹⁶Hospital Universitario de Canarias, Santa Cruz de Tenerife, La Laguna, ESP
¹⁷Hospital Universitari i Politècnic La Fe, Catholic University of Valencia, Valencia, Spain
¹⁸Hospital Universitario Puerta de Hierro, Madrid, Spain
¹⁹Hospital Clínico Universitario Virgen de la Arrixaca. IMIB-Arrixaca. University of Murcia, Murcia, ESP
²⁰Hospital Universitario Clínico San Carlos, Madrid, Spain
²¹Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
²²Hospital Universitario Son Llatzer, Institut d’ investigacio Illes Balears (IdISBa), Palma de Mallorca, Spain
²³Amyloidosis and Myeloma Unit, Hospital Clínic, Barcelona, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
²⁴Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain
²⁵Hematology Department, Clínica Universidad De Navarra, Pamplona, Spain
²⁶Instituto de Investigación del Hospital Universitario 12 de Octubre, European Network, Spain
²⁷Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Salamanca, Spain
²⁸CIBERONC, Salamanca, Spain
²⁹Hospital Universitario Salamanca, IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain

5:30 PM

545

Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma

Anil Aktas-Samur, PhD¹^*, Mariateresa Fulciniti, PhD², Sanika Derebail, MS³^*, Raphael Szalat, MD, PhD⁴, Giovanni Parmigiani, PhD⁵^*, Jill Corre⁶^*, Herve Avet-Loiseau⁷^*, Mehmet K. Samur, PhD⁸ and Nikhil C. Munshi, MD, PhD⁹

¹Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
²Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
³Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Department of Hematology and Medical Oncology, Boston University Medical Center, Boston, MA
⁵Dana-Farber Cancer Institute, Boston, MA
⁶Unité de Génomique du Myélome, IUCT- Oncopole, Toulouse, France
⁷Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France
⁸Department of Data Science, Dana-Farber Cancer Institute, Harvard TH Chan School of Public Health, Boston, MA
⁹Dana-Farber Cancer Institute, Harvard Medical School, Boston

5:45 PM

546

Circulating Plasma Cells Are the Most Powerful Prognostic Marker in Transplant Ineligible Multiple Myeloma with 2% As a New Cut-Off for Primary Plasma Cell Leukemia

Tomas Jelinek¹, Renata Bezděková²^*, David Zihala³^*, Tereza Sevcikova³^*, Lenka Capkova⁴^*, Petra Polackova²^*, Martin Stork⁵^*, Zdenka Knechtova²^*, Ondrej Venglar, MSc⁶^*, Artur Jurczyszyn, MD⁷^*, Jorge J. Castillo, MD⁸, Miroslav Penka²^*, Jakub Radocha, MD, PhD⁹^*, Sabina Sevcikova¹⁰, Ludek Pour, MD⁵^*, Lucie Rihova²^* and Roman Hajek, MD, PhD¹

¹Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
²Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic
³Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
⁴Institute of biostatistics and analyses, Ltd., Brno, Czech Republic
⁵Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
⁶Faculty of Science, University of Ostrava, Ostrava, Czech Republic
⁷Plasma Cell Dyscrasia Center, Jagiellonian University Department of Hematology, Faculty of Medicine,, Kraków, Poland
⁸Dept. of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Bing Center for Waldenström Macroglobulinemia, Boston, MA
⁹4th Department of Internal Medicine – Hematology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic
¹⁰Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, LF Masaryk University, Brno, Czech Republic

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

652.O2.6 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Reoptimizing Standards and Redefining Approaches